Mainstreaming genetic testing within oncology services enables timely diagnosis and treatment stratification for Lynch syndrome, yet its adoption remains inconsistently implemented across healthcare systems, according to a review published in Hereditary Cancer in Clinical Practice. Lynch syndrome represents one of the most common inherited cancer predispositions, and widespread tumour-based screening combined with expanded awareness and access to germline genetic testing has substantially increased the identification of affected individuals. However, variable integration of genetics into routine cancer care pathways and fragmented service delivery continue to present major obstacles to optimal patient management.
Individuals identified with Lynch syndrome are confronted with complex and highly personal decisions across their lifespan regarding cancer surveillance, risk-reduction strategies, and targeted therapies such as immunotherapy. The review authors determined that routine care pathways frequently fail to deliver coordinated support, leaving patients to navigate disparate services during critical stages of care. System-level barriers, workforce capacity limitations, rapidly evolving clinical guidelines, and fragmented communication across medical teams all contribute to the uneven implementation of genetic testing and ongoing management.
This suboptimal coordination has direct and detrimental consequences for clinical outcomes and patient experience. The review notes that fragmented pathways adversely affect the uptake of routine cancer surveillance protocols and impede cascade testing, which is vital for identifying at-risk biological relatives. Furthermore, the authors observe that these coordination failures and structural barriers hold the potential to exacerbate existing health inequities among diverse patient groups navigating hereditary cancer care.
To investigate these systemic challenges, the authors synthesised clinical, research, and policy evidence alongside direct insights generated through patient and public involvement. The review incorporated personal narratives from three patient advocate co-authors who contributed their lived experience with Lynch syndrome. These personal perspectives were complemented by broader viewpoints informed by direct engagement with international patient and advocacy networks, ensuring that real-world patient challenges informed the evaluation.
The authors emphasize that translating advances in tumour profiling and immunotherapy into sustained clinical benefits requires robust multidisciplinary integration. Routine cancer pathways must actively connect molecular pathology, precision oncology, clinical genetics, peer support services, and psychosocial care. Insights derived from lived experience specifically highlight the necessity of establishing clear clinical ownership, ensuring longitudinal follow-up, fostering shared decision-making, and delivering continuous psychosocial support across the entire lifespan.
To address fragmented service delivery, the review outlines an integrated, lifespan-oriented framework designed to embed structured management directly within routine cancer services. This proposed model incorporates centralised coordination, interoperable digital tools, and joined-up cross-specialty guidelines to align disparate clinical teams. The framework also calls for dedicated clinician and patient education, codesigned care pathways, and proactive genetic and psychosocial counselling delivered at key life transitions.
The authors conclude that adopting a patient-centred, lifespan-oriented approach is essential to optimise cancer prevention, early detection, treatment outcomes, and overall quality of life for individuals with Lynch syndrome. Embedding patient and public involvement, workforce education, and comprehensive system integration within routine cancer pathways establishes a scalable care delivery model. According to the review, this integrated approach may also provide valuable guidance for structuring care delivery across other hereditary cancer predispositions.
The review emphasizes that achieving sustained benefits from tumour profiling and targeted treatments requires close integration among clinical genetics, precision oncology, and molecular pathology. Although widespread tumour screening and germline testing identify more individuals with Lynch syndrome, system barriers and workforce capacity limits continue to hinder timely diagnosis and treatment stratification. By establishing joined-up cross-specialty guidelines and dedicated workforce education, health services can overcome fragmented communication and inconsistent implementation across routine care pathways.
Furthermore, insights from international patient networks and lived experience narratives demonstrate that management must operate across the lifespan rather than in isolation. Proactive genetic and psychosocial counselling at key life stages supports shared decision-making, clear clinical ownership, and longitudinal follow-up. Embedding centralized coordination and interoperable digital tools into routine services also strengthens cascade testing and surveillance uptake while addressing potential health inequities, providing a scalable model to optimize prevention, early detection, and quality of life.
Subject of Research: Lifespan-oriented Lynch syndrome management and genetic testing integration in routine cancer pathways
Article Title: Integrating Lynch syndrome management into routine cancer pathways: a lifespan-oriented approach to patient-centred care and shared decision-making
Article References: Kohut, K., Wehbe, M., Hoffmann, G., Smith, T., Horgan, R., Repana, D., Robinson, N., & Shiu, K.-K. (2026). Integrating Lynch syndrome management into routine cancer pathways: a lifespan-oriented approach to patient-centred care and shared decision-making. Hereditary Cancer in Clinical Practice. https://doi.org/10.1186/s13053-026-00360-z
Image Credits: AI Generated
DOI: 10.1186/s13053-026-00360-z
Keywords: Lynch syndrome, genetic testing, cancer care pathways, precision oncology, tumour profiling, immunotherapy, cascade testing, cancer surveillance, patient-centred care, shared decision-making, psychosocial care, molecular pathology, clinical genetics, hereditary cancer, health inequities, digital tools, patient advocacy, cross-specialty guidelines
News Source: Nathaniel Bowman. (November 17, 2026). Mainstream Lynch Syndrome Genetic Testing Faces Systemic Barriers Across Cancer Pathways. Scienmag.



